Lets patients with serious mental illness get faster access to new psychedelic therapies.
This bill would speed up the development and availability of psychedelic drugs for serious mental illnesses. It would clarify how patients can access experimental Schedule I drugs under "right to try" laws and require the Department of Veterans Affairs to prepare for these new treatments. Drug makers would also get incentives for developing important new medicines.
Today, the Controlled Substances Act restricts experimental Schedule I drugs. Also, the process for adjusting drug production quotas does not always account for rapid clinical developments. After this bill, the Attorney General would need to quickly review Schedule I drugs for rescheduling after successful clinical trials. This includes ibogaine within 60 days. The FDA would also offer vouchers for priority review of important new drugs. A special DEA registration process would allow physicians to administer experimental Schedule I drugs under "right to try" laws.
HR 9559 · 119th Congress · June 30, 2026 · AI Summary by gemini-2.5-flash · 10/10
Sign in to see your representatives' phone numbers